Laura Janzen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Janzen has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Brenda J. Spiegler
The Hospital for Sick Children, Toronto, Ontario, Canada
2 shared publicationsDonald Mabbott
The Hospital for Sick Children
2 shared publications- Angela Yohan
The Hospital for Sick Children
1 shared publication - Caelyn Smith
The Hospital for Sick Children
1 shared publication - Cory Murphy
The Hospital for Sick Children
1 shared publication Dana David
The Hospital for Sick Children, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- 23 October 2024
- Published by Springer Nature
- p. 495-515
The Role of Allied Healthcare Professionals in the Care of Pediatric Brain Tumor Patients and Their Families
- 23 October 2024
- Published by Springer Nature
- p. 495-515
The Role of Allied Healthcare Professionals in the Care of Pediatric Brain Tumor Patients and Their Families
- 23 October 2024
- Published by Springer Nature
- p. 425-436
Neuropsychological Outcomes in Pediatric Brain Tumor Survivors
- 23 October 2024
- Published by Springer Nature
- p. 425-436
Neuropsychological Outcomes in Pediatric Brain Tumor Survivors
- 23 May 2019
- Published by Springer Nature
- p. 133-146
Paediatric Neuro-Oncology: Medulloblastoma
- 14 September 2016
- Published by Elsevier in The Lancet Psychiatry
- Vol. 3 (10) , 912-913
Long-term neurocognitive and functional effects of treatment for childhood acute lymphoblastic leukaemia.
- 14 September 2016
- Published by Elsevier in The Lancet Psychiatry
- Vol. 3 (10) , 912-913
Long-term neurocognitive and functional effects of treatment for childhood acute lymphoblastic leukaemia.
- 25 August 2015
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (12) , 2183-2188
Pre-Morbid Developmental Vulnerabilities in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Not all children with acute lymphoblastic leukemia (ALL) were developing in a typical manner prior to diagnosis. Pre-existing developmental vulnerabilities (DV) may be related to long-term neuropsychological sequelae following ALL treatment, yet little is known about the prevalence or nature of prior DV in this population. Children with newly diagnosed ALL aged 2–18 years (n = 115) were screened for DV by asking parents about the child's prior developmental history and with the Developmental Profile-3 (DP-3). Twenty-six participants (23% of total sample) screened positive for prior DV, with one or more of the following: delayed early motor and/or language milestones that required intervention (n = 17), prior diagnosis of Down syndrome (n = 3), prior diagnosis of autism spectrum disorder (n = 1), prior diagnosis of attention-deficit/hyperactivity disorder and/or learning disability (n = 6), or prior neurological conditions (n = 5). A sizable proportion of children with newly diagnosed ALL have pre-morbid DV that could potentially make them more vulnerable to reduced educational opportunities during treatment and neurotoxic late effects following treatment. Identification of the subset of children with ALL and DV is essential to direct early interventions and to study their long-term outcomes. Pediatr Blood Cancer
- 25 August 2015
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (12) , 2183-2188
Pre-Morbid Developmental Vulnerabilities in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Not all children with acute lymphoblastic leukemia (ALL) were developing in a typical manner prior to diagnosis. Pre-existing developmental vulnerabilities (DV) may be related to long-term neuropsychological sequelae following ALL treatment, yet little is known about the prevalence or nature of prior DV in this population. Children with newly diagnosed ALL aged 2–18 years (n = 115) were screened for DV by asking parents about the child's prior developmental history and with the Developmental Profile-3 (DP-3). Twenty-six participants (23% of total sample) screened positive for prior DV, with one or more of the following: delayed early motor and/or language milestones that required intervention (n = 17), prior diagnosis of Down syndrome (n = 3), prior diagnosis of autism spectrum disorder (n = 1), prior diagnosis of attention-deficit/hyperactivity disorder and/or learning disability (n = 6), or prior neurological conditions (n = 5). A sizable proportion of children with newly diagnosed ALL have pre-morbid DV that could potentially make them more vulnerable to reduced educational opportunities during treatment and neurotoxic late effects following treatment. Identification of the subset of children with ALL and DV is essential to direct early interventions and to study their long-term outcomes. Pediatr Blood Cancer
- 1 January 2015
- Published by Springer Nature
- p. 267-276
Neuropsychological Outcomes in Pediatric Brain Tumor Survivors
- 1 January 2015
- Published by Springer Nature
- p. 267-276
Neuropsychological Outcomes in Pediatric Brain Tumor Survivors
- 15 January 2010
- Published by Taylor & Francis in The Clinical Neuropsychologist
- Vol. 24 (2) , 358-360
The Evolution of Clinical Child Neuropsychology
- 15 January 2010
- Published by Taylor & Francis in The Clinical Neuropsychologist
- Vol. 24 (2) , 358-360
The Evolution of Clinical Child Neuropsychology
- 1 January 2008
- Published by Wiley in Developmental Disabilities Research Reviews
- Vol. 14 (3) , 185-195
Neurodevelopmental sequelae of pediatric acute lymphoblastic leukemia and its treatment
This review will describe the neurocognitive outcomes associated with pediatric acute lymphoblastic leukemia (ALL) and its treatment. The literature is reviewed with the aim of addressing methodological issues, treatment factors, risks and moderators, special populations, relationship to neuroimaging findings, and directions for future research. It is concluded that neurocognitive outcomes for the majority of children with standard‐risk ALL treated according to current chemotherapy protocols is relatively good, but subgroups of children are more significantly compromised. As medical treatments advance and survival rates continue to improve, neurocognitive outcomes and other quality of life indicators will become increasingly important. Preventing or ameliorating treatment‐related neuropsychological sequelae represents the next major challenge in pediatric ALL. © 2008 Wiley‐Liss, Inc. Dev Disabil Res Rev 2008;14:185–195.
- 1 January 2008
- Published by Wiley in Developmental Disabilities Research Reviews
- Vol. 14 (3) , 185-195
Neurodevelopmental sequelae of pediatric acute lymphoblastic leukemia and its treatment
This review will describe the neurocognitive outcomes associated with pediatric acute lymphoblastic leukemia (ALL) and its treatment. The literature is reviewed with the aim of addressing methodological issues, treatment factors, risks and moderators, special populations, relationship to neuroimaging findings, and directions for future research. It is concluded that neurocognitive outcomes for the majority of children with standard‐risk ALL treated according to current chemotherapy protocols is relatively good, but subgroups of children are more significantly compromised. As medical treatments advance and survival rates continue to improve, neurocognitive outcomes and other quality of life indicators will become increasingly important. Preventing or ameliorating treatment‐related neuropsychological sequelae represents the next major challenge in pediatric ALL. © 2008 Wiley‐Liss, Inc. Dev Disabil Res Rev 2008;14:185–195.